Skip to content
PubMed This is a summary of 6 peer-reviewed journal articles Updated
Clinical Genetics · GLS Gain-of-Function Disorder and MSMO1 Deficiency

Diagnostic Testing and Understanding Lab Reports

At a Glance

Evaluating suspected GLS gain-of-function disorder or MSMO1 deficiency may require brain MRS, amino-acid testing, plasma sterol profiling, and genetic analysis. No single result is diagnostic, so an experienced metabolic laboratory must interpret the findings together.

Diagnosing an ultra-rare metabolic disorder is like solving a high-stakes puzzle where many pieces look the same. To distinguish between conditions like GLS gain-of-function and MSMO1 deficiency, doctors use specialized tests that look at the chemistry of the brain, blood, and urine.

Understanding these reports can help you ensure your child’s medical team has all the information they need to provide a precise diagnosis. However, these tests require interpretation by an experienced metabolic laboratory; standard fibroblast assays are not routine amino-acid panels.

Mapping the Brain’s Chemistry: MRS

While a standard MRI looks at the structure of the brain, a Magnetic Resonance Spectroscopy (MRS) scan looks at its chemistry. It measures the concentration of specific molecules, creating a “graph” of peaks and valleys [1]. MRS is a selected adjunct rather than a usual requirement.

In selected cases of a GLS gain-of-function variant, the MRS report has shown:

  • High Glutamate / Low Glutamine: Some reported cases note extremely high glutamate and nearly undetectable glutamine [1][2]. However, in clinical MRS, glutamate and glutamine peaks can overlap and may be reported together as Glx. Interpretation depends on field strength, acquisition quality, age, and medications.

Specialized Metabolic Lab Panels

Common blood tests often miss these rare markers. You may see two specific types of “advanced” metabolic panels on your child’s reports.

Amino Acid Analysis (Blood, Urine, or Fibroblasts)

This test measures levels of chemical building blocks. In GLS variants, the key is the balance between two specific amino acids.

  • Glutamate-High / Glutamine-Low: This pattern is often seen in the urine and even in specialized fibroblasts (skin cells) of affected children in reported literature [1]. However, these values provide no general diagnostic cutoff on their own [1].

Sterol Profiling (MSMO1 Deficiency)

If MSMO1 deficiency is suspected, a standard cholesterol test is not enough. Doctors must order a plasma sterol profile that looks for “intermediates”—the molecules the body makes on the way to creating cholesterol [3].

  • C4-Methylsterols: The report will look for an accumulation of C4-monomethyl and C4-dimethyl sterols [3][4]. These are the specific “unfinished” parts that build up when the MSMO1 enzyme is not working [5].

Reading the Genetic Report (WES/WGS)

Genetic testing, such as Whole Exome Sequencing (WES) or Whole Genome Sequencing (WGS), looks for variations in your child’s DNA.

  • De Novo Variants (GLS): This means the variant is brand new in the child [1]. If the report says “Heterozygous de novo,” it means only one copy of the gene is affected. A true de novo variant generally has a low recurrence risk in future pregnancies, though parental mosaicism leaves a non-zero risk [2]. However, “de novo” does not by itself establish a pathogenic gain-of-function variant.
  • Biallelic Variants (MSMO1): This is an autosomal recessive condition. The child inherited two non-working copies of the gene [3]. The report may use terms like homozygous or compound heterozygous [4][6]. For confirmed MSMO1 carriers, there is typically a 25% risk per pregnancy.
  • VUS (Variant of Uncertain Significance): A VUS must not be used to diagnose the child or direct treatment.

Completeness Checklist for Lab Reports

Use this checklist when reviewing your child’s records:

  • [ ] Brain MRS: Does the report specify levels for Glutamate/Glutamine, or are they grouped as Glx? [1]
  • [ ] Amino Acid Panel: Are both glutamate and glutamine reported? [1]
  • [ ] Sterol Profile: Does it specifically list C4-monomethyl and C4-dimethyl sterols? [3]
  • [ ] Genetic Testing: If a variant was found, was segregation testing done (testing the parents) to confirm if it is de novo or inherited? [4][3]

Common questions in this guide

What can a brain MRS scan show when a GLS gain-of-function disorder is suspected?
Magnetic Resonance Spectroscopy examines brain chemistry rather than brain structure. Some reported GLS gain-of-function cases show high glutamate and very low glutamine, but the two signals can overlap and be reported together as Glx. Results depend on scan quality, field strength, age, and medications, so an MRS result is not interpreted by itself.
Which amino acid results are important when GLS variants are being evaluated?
The report should show both glutamate and glutamine, because some reported GLS variants are associated with a high-glutamate and low-glutamine pattern in blood, urine, or specialized fibroblast testing. There is no general diagnostic cutoff that can be used alone. An experienced metabolic laboratory must interpret the results in context.
How is MSMO1 deficiency tested?
A standard cholesterol test is not sufficient to evaluate MSMO1 deficiency. Doctors typically order a plasma sterol profile that looks for buildup of C4-monomethyl and C4-dimethyl sterols, which are intermediates in cholesterol production.
What do de novo and biallelic mean on a genetic report?
A de novo GLS variant is new in the child rather than inherited from either parent, although parental mosaicism can leave some recurrence risk. Biallelic MSMO1 variants mean that both copies of the gene have a variant, often described as homozygous or compound heterozygous. If both parents are confirmed MSMO1 carriers, the typical chance of an affected child is 25% in each pregnancy.
Can a variant of uncertain significance in GLS confirm the diagnosis?
No. A variant of uncertain significance should not be used by itself to diagnose a child or guide treatment. The care team may discuss additional evidence or specialized functional studies, but the result requires expert interpretation.
Why is testing both parents useful after a GLS or MSMO1 variant is found?
Parental segregation testing can show whether a GLS variant is truly de novo or inherited. For MSMO1, it can help determine whether two variants are in trans, meaning they are on opposite copies of the gene, which supports interpretation of an autosomal recessive disorder.

Get notified when new evidence is published on infantile cataract, skin abnormalities, glutamate excess, and impaired intellectual development.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (6)
  1. 1

    GLS hyperactivity causes glutamate excess, infantile cataract and profound developmental delay.

    Rumping L, Tessadori F, Pouwels PJW, et al.

    Human molecular genetics 2019; (28(1)):96-104 doi:10.1093/hmg/ddy330.

    PMID: 30239721
  2. 2

    Structure and enzymology of glutaminase S482C and H461L variants associated with excess brain glutamate and neurological disease.

    Crane CS, McIssac TK, Milano SK, et al.

    The Journal of biological chemistry 2026; (302(6)):113091 doi:10.1016/j.jbc.2026.113091.

    PMID: 42055345
  3. 3

    A rare case of sterol-C4-methyl oxidase deficiency in a young Italian male: Biochemical and molecular characterization.

    Frisso G, Gelzo M, Procopio E, et al.

    Molecular genetics and metabolism 2017; (121(4)):329-335 doi:10.1016/j.ymgme.2017.06.013.

    PMID: 28673550
  4. 4

    New Homozygous Missense MSMO1 Mutation in Two Siblings with SC4MOL Deficiency Presenting with Psoriasiform Dermatitis.

    Kalay Yildizhan I, Gökpınar İli E, Onoufriadis A, et al.

    Cytogenetic and genome research 2020; (160(9)):523-530 doi:10.1159/000511126.

    PMID: 33161406
  5. 5

    Cholesterol synthesis enzyme SC4MOL is fine-tuned by sterols and targeted for degradation by the E3 ligase MARCHF6.

    Qian L, Scott NA, Capell-Hattam IM, et al.

    Journal of lipid research 2023; (64(5)):100362 doi:10.1016/j.jlr.2023.100362.

    PMID: 36958722
  6. 6

    MSMO1 deficiency: a potentially partially treatable, ultrarare neurodevelopmental disorder with psoriasiform dermatitis, alopecia and polydactyly.

    Tkemaladze T, Bratland E, Bregvadze K, et al.

    Clinical dysmorphology 2023; (32(3)):97-105 doi:10.1097/MCD.0000000000000461.

    PMID: 37195326

This page is for informational purposes only and does not constitute medical advice. A metabolic specialist, genetic counselor, and experienced laboratory should interpret your child’s MRS, biochemical, and genetic results.